Postcesarean Pain Relief
Conditions
Brief summary
Objective: To evaluate intraperitoneal (IP) lidocaine administration and intravenous (IV) lidocaine infusion for postoperative pain control after cesarean section. Study design: prospective randomized, double-blind, placebo-controlled study. Patients and methods: Initially, 165 pregnant full-term females, indicated to be underwent elective cesarean delivery for various indications were randomized equally to either group C (control, IP and IV saline), group IP (intraperitoneal lidocaine administration), or group IV (intravenous lidocaine infusion).Five patients were excluded from each group for various reasons. The outcome measures were postoperative pain scoring, total pethidine consumption and the need for postoperative analgesia.
Interventions
Normal saline in a volume equivalent to that used in intravenous lidocaine group
Patients received 00 ml of saline intraperitoneally
Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure.
Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery.
Sponsors
Benha University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* Singleton pregnancy, more than or equal completed 37 gestational weeks, indicated to undergo elective cesarean delivery for various indications
Exclusion criteria
* extreme of age (below 18 or above 40 year), uncooperative patients, women under spinal anesthesia, previous abdominal scars, including previous cesarean or myomectomy, multiple gestation, BMI \>35 kg/m², chorioamnionitis, hypersensitivity or contraindications to lidocaine, bronchial asthma, bleeding diathesis, pregnancy induced-hypertension, liver or kidney diseases, diabetes mellitus, and patients with psychological disturbance, or any form of chronic pain before or during pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative pain scoring (number) | First 24 hours postoperative |
Secondary
| Measure | Time frame |
|---|---|
| Total pethidine consumption in 24 hours (mg) | First 24 hours postoperative |
| The time to bowel sounds, hours | First 3 days postoperative |
| The need for rescue postoperative analgesia. | First 24 hours postoperative |
| Duration of hospital stay , days | First 3 days postoperative |
| Any reported side effects | First 3 days postoperative |
| The time to start regular diet, days | First 3 days postoperative |
Outcome results
None listed